| Immune-mediated neurological syndromes in SARS-CoV-2-infected patients A Guilmot, S Maldonado Slootjes, A Sellimi, M Bronchain, B Hanseeuw, ... Journal of neurology 268, 751-757, 2021 | 197 | 2021 |
| Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? M D'haeseleer, S Hostenbach, I Peeters, SE Sankari, G Nagels, ... Journal of Cerebral Blood Flow & Metabolism 35 (9), 1406-1410, 2015 | 139 | 2015 |
| Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management B Decallonne, E Bartholomé, V Delvaux, M D’haeseleer, S El Sankari, ... Acta Neurologica Belgica 118, 153-159, 2018 | 38 | 2018 |
| Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients F London, S El Sankari, V Van Pesch Clinical Neurophysiology 128 (4), 561-569, 2017 | 37 | 2017 |
| Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus X Finné Lenoir, C Sindic, V Van Pesch, S El Sankari, M de Tourtchaninoff, ... Neurocritical care 18, 89-92, 2013 | 31 | 2013 |
| Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis M Valet, M Quoilin, T Lejeune, G Stoquart, V Van Pesch, S El Sankari, ... CNS drugs 33, 1087-1099, 2019 | 30 | 2019 |
| Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis C Druart, S El Sankari, V Van Pesch Patient related outcome measures, 1-10, 2017 | 30 | 2017 |
| Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program V Van Pesch, E Bartholomé, V Bissay, O Bouquiaux, M Bureau, ... Acta neurologica belgica 114, 167-178, 2014 | 22 | 2014 |
| Correlation between tap test and CSF aqueductal stroke volume in idiopathic normal pressure hydrocephalus SE Sankari, A Fichten, C Gondry-Jouet, M Czosnyka, D Legars, ... Hydrocephalus: Selected Papers from the International Workshop in Crete …, 2012 | 22 | 2012 |
| Fatigue and physical fitness of mildly disabled persons with multiple sclerosis: a cross-sectional study M Valet, T Lejeune, Y Glibert, JC Hakizimana, V Van Pesch, S El Sankari, ... International Journal of Rehabilitation Research 40 (3), 268-274, 2017 | 21 | 2017 |
| B cell depletion therapy does not resolve chronic active multiple sclerosis lesions P Maggi, CV Bulcke, E Pedrini, C Bugli, A Sellimi, M Wynen, A Stölting, ... EBioMedicine 94, 2023 | 19 | 2023 |
| Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab S El Sankari, G Dahlqvist, L Monino, V Van Pesch Acta Neurologica Belgica 118, 331-333, 2018 | 13 | 2018 |
| Telecommunication and rehabilitation for patients with multiple sclerosis: access and willingness to use. A cross-sectional study C Remy, M Valet, G Stoquart, S El Sankari, V Van Pesch, A De Haan, ... Eur J Phys Rehabil Med 56 (4), 403-411, 2020 | 12 | 2020 |
| Ventricular arrhythmia in a male MS patient on fingolimod V Van Pesch, S Marchandise, S El Sankari, C Sindic Acta Neurologica Belgica 115, 77-79, 2015 | 6 | 2015 |
| Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. a crossover, double-blinded, placebo-controlled study M Valet, S El Sankari, V Van Pesch, C Detrembleur, T Lejeune, ... Clinical Biomechanics 86, 105382, 2021 | 4 | 2021 |
| Cognitive trajectories in relapsing-remitting multiple sclerosis: Evidence of multiple evolutionary trends F London, A De Haan, Z Benyahia, G Landenne, T Duprez, V van Pesch, ... Multiple sclerosis and related disorders 77, 104848, 2023 | 3 | 2023 |
| Improvement in progressive multifocal leukoencephalopathy after pembrolizumab‐induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma I Dufour, T Duprez, M Wertz, P Saussoy, N Ackermans, S El Sankari, ... EJHaem 1 (2), 585-588, 2020 | 3 | 2020 |
| Telecommunication and rehabilitation among patients with multiple sclerosis: access and willingness to use C Remy, M Valet, G Stoquart, S El Sankari, V Van Pesch, A De Haan, ... Annals of Physical and Rehabilitation Medicine 61, e99, 2018 | 3 | 2018 |
| Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients SE Sankari, C Van Essche, V Van Pesch Journal of neurology 268 (11), 4376-4378, 2021 | 2 | 2021 |
| The BELTRIMS registry: real-world safety and efficacy of DMTs in Belgium B Willekens, V Van Pesch, M D'Hooghe, D Dive, B Dubois, R Bouton, ... Multiple Sclerosis 24, 920-920, 2018 | 2 | 2018 |
